Switching Imids: The Optimismm Trials Impact On Mm | Latest News RSS feed

Switching Imids: The Optimismm Trials Impact On Mm - Latest News


Celgene (CELG) Q3 2016 Results - Earnings Call Transcript

Furthermore, we are excited about the REVLIMID myeloma data to be presented at ASH this year, including final overall survival data for MM-020 and key analysis ... Our Phase III OPTIMISMM trial in com... read more

Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018

sequencing using data from The Connect ® MM Patient Registry. (Jagannath) Relapsed/Refractory Multiple Myeloma Abstract #S847; Oral; Saturday, June 16, 16:00 – 16:15, Room A1. OPTIMISMM: Phase III tri... read more

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

1 Department of Medicine, Division of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA Correspondence: Dr AA Kassim, Division of Hematology/Stem Cell Transplant, Vande... read more

Looking for another news?


An Assessment Of Celgene's Deal For Receptos

How ozanimod fits into Celgene's business plan Celgene's main products, namely Revlimid and the other IMiDs, are immuno-oncology products ... However, efficacy in MS was substantial in the Phase 2 tri... read more


Bone marrow microenvironment and the identification of new targets for myeloma therapy

Most prominently, Bort, Thal and the IMiDs have already significantly changed treatment strategies in MM during the last 5 years. The non-cellular BM compartment is composed of the ECM including fibro... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us